PNC Financial Services Group’s MoonLake Immunotherapeutics MLTX Stock Holding History

PNC Financial Services Group’s Portfolio MLTX Stock Details MLTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$224	Sell	12 -35	-74%	-$580	﹤0.01%	5021
2025 Q4	$620	Sell	47 -12	-20%	-$142	﹤0.01%	4792
2025 Q3	$424	Sell	59 -4,281	-99%	-$223K	﹤0.01%	4837
2025 Q2	$205K	Sell	4,340 -4,860	-53%	-$198K	﹤0.01%	2187
2025 Q1	$359K	Buy	9,200 +700	+8%	+$30.2K	﹤0.01%	1764
2024 Q4	$460K	Buy	8,500 +320	+4%	+$16.3K	﹤0.01%	1600
2024 Q3	$412K	Buy	8,180 +44	+0.5%	+$2.06K	﹤0.01%	1675
2024 Q2	$358K	Buy	8,136 +1,322	+19%	+$56K	﹤0.01%	1730
2024 Q1	$342K	Buy	6,814 +667	+11%	+$36.2K	﹤0.01%	1792
2023 Q4	$371K	Buy	6,147 +2,067	+51%	+$107K	﹤0.01%	1699
2023 Q3	$233K	Sell	4,080 -247	-6%	-$13.6K	﹤0.01%	2009
2023 Q2	$221K	Buy	+4,327	New	+$116K	﹤0.01%	2127

Other funds holding MLTX

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return

CAM

Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

WAM

Weiss Asset Management Boston, Massachusetts $5.91B AUM 42.42% 1-Year Est. Return

LGM

Logos Global Management San Francisco, California $2B AUM 444.09% 1-Year Est. Return

Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

PNC Financial Services Group's MLTX Position: Q1 2026 in Review

PNC Financial Services Group reduced its MoonLake Immunotherapeutics (MLTX) stake by 74% in Q1 2026, selling an estimated $580 and leaving 12 shares worth $224. The position accounts for ﹤0.01% of the portfolio, ranked #5021.

PNC Financial Services Group first reported a position in MLTX in Q2 2023 and has held it in 12 quarters since. The position peaked at $460K in Q4 2024. 147 funds tracked by Wall St. Rank hold MLTX as of Q1 2026.

PNC Financial Services Group held 12 shares of MoonLake Immunotherapeutics worth $224 as of Q1 2026.
PNC Financial Services Group sold 35 MoonLake Immunotherapeutics shares in Q1 2026, an estimated $580.
MoonLake Immunotherapeutics made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #5021 holding.
PNC Financial Services Group first reported a position in MoonLake Immunotherapeutics in Q2 2023 and has held it in 12 quarters since.
PNC Financial Services Group's MoonLake Immunotherapeutics position peaked at $460K in Q4 2024.
147 funds tracked by Wall St. Rank held MoonLake Immunotherapeutics as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.